DenSeeMammo
Statlife • Radiology • 06/26/2018
Device Purpose
DenSeeMammo is a software application designed to assist radiologists by providing an automated estimation of BI-RADS breast density categories from digital 2D mammograms. It achieves this by employing proprietary algorithms to analyze processed images and compare them against a qualified database of previously assessed mammograms, thereby offering adjunctive information to aid in breast density assessment.
Summary
DenSeeMammo version 1.2 is a software application designed to assist radiologists by estimating breast density from Full Field Digital Mammography (FFDM) images. It analyzes processed 2D digital mammograms using a fully automated comparison procedure to provide a BI-RADS 5th Edition breast density category. This adjunctive information is intended to aid in the assessment of breast density for both symptomatic and asymptomatic women undergoing mammography, but the final determination remains with an MQSA qualified interpreting physician. The software is compatible with DICOM images obtained from GE Senographe Essentials and Hologic Selenia Dimension systems and can process either single-view or two-view (craniocaudal and mediolateral oblique) mammograms. The software employs proprietary algorithms to compare patient images against qualified databases of mammograms previously assessed visually by radiologists according to ACR BI-RADS V recommendations, reporting results per patient based on the maximum density of the two breasts. Developed in Java and operating in a client-server architecture on a local network, DenSeeMammo's core is built for OS X, while its web-based graphical user interface is accessible on Windows, OS X, and Linux. Performance testing, including reproducibility studies, comparisons with expert radiologist assessments, and beta site clinical validation, demonstrated the software's ability to meet predefined acceptance criteria for accurate density estimation and system integration.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the performance of DenSeeMammo's automated BI-RADS categorization compare to inter-radiologist variability in breast density assessment, particularly across the different BI-RADS categories?; What specific image features or proprietary algorithms does DenSeeMammo utilize to differentiate between the BI-RADS density categories, and how were these algorithms validated against diverse patient populations and image qualities?; What is the quantitative impact on radiologists' workflow efficiency and assessment consistency when integrating DenSeeMammo as an adjunctive tool?; How does the software handle images with artifacts or unusual anatomical presentations, and what mechanisms are in place to flag cases where automated assessment might be less reliable?; What is the scalability of the "qualified databases" used for comparison, and how frequently are these databases updated or expanded to maintain accuracy with evolving imaging technologies and demographic shifts?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM, SaaSBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Postmarket cybersecurity monitoring plan not clearly documented in AI-generated device summary.
• Not detected in AI-generated device summary: SBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly